Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Predicted Market Size Of The Viral And Non-Viral Vector Manufacturing Industry By 2029?
The market for viral and non-viral vector manufacturing has seen swift expansion in the past few years. The market size is projected to surge from $8.67 billion in 2024 to $10.28 billion in 2025, marking a compound annual growth rate (CAGR) of 18.5%. The historical growth can be linked to factors such as the increased occurrence of genetic conditions, advancements in the field of biotechnology, a rise in investment towards gene therapy research, a heightened awareness of personalized medicine, and regulatory backing for the progression of gene therapy.
Expectations indicate a robust upswing in the market for manufacturing viral and non-viral vectors in the upcoming years. By 2029, this market is forecasted to expand to $22.01 billion, encountering a compound annual growth rate (CAGR) of 21.0%. Several factors contribute to this predicted increase, including an escalated demand for gene therapies, broader application in treating rare diseases, increased funding for biomanufacturing infrastructure, and the rising preference for precision medicine. The forecast period also anticipates significant trends such as the emergence of next-generation viral vectors, enhanced usage of CRISPR or cas9 technology in vector production, a focus on scalable and cost-efficient procedures, increasing utilization of non-viral vectors, and advances in cell and gene therapy manufacturing techniques.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp
Which Factors Are Steering Growth In The Viral And Non-Viral Vector Manufacturing Market?
The surge in the appearance of genetic disorders is anticipated to catalyze the expansion of the viral and non-viral vector manufacturing markets in the future. These disorders come about due to deviations in the standard DNA sequence either completely or partially. Therapeutic genes are transferred to target cells by viral vectors, a process which compensates for or even swaps out the faulty genes contributing to genetic disorders. In contrast, non-viral vectors are frequently employed in ex vivo gene therapy techniques, wherein the genetic modification of cells occurs outside the body before being re-administered to the patient. As an example, the International Diabetes Federation based in Belgium reported in June 2022 that the prevalence of diabetes globally had risen to 10.5%, with more than half (44.7%) of affected people remaining undiagnosed and approximately 783 million adults (or one-eight of the population) predicted to be diabetic by 2045. Thus, the escalation in genetic disorders propels the growth of the viral and non-viral vector manufacturing market.
Which Segment Accounts For The Largest Share In The Viral And Non-Viral Vector Manufacturing Market?
The viral and non-viral vector manufacturingmarket covered in this report is segmented –
1) By Vector Type: Viral Vector; Non-Viral Vector
2) By Disease: Cancer; Genetic Disease; Infectious Disease; Cardiovascular Disease; Other Diseases
3) By Application: Gene Therapy; Vaccinology; Cell Therapy; Other Applications
Subsegments:
1) By Viral Vector: Adenoviral Vectors; Lentiviral Vectors; AAV (Adeno-Associated Virus) Vectors; Retroviral Vectors; Other Viral Vectors
2) By Non-Viral Vector: Plasmid DNA; Lipid-Based Vectors; Nanoparticles; Electroporation-Based Vectors; Other Non-Viral Vectors
Which Disruptive Trends Are Driving Change Across The Viral And Non-Viral Vector Manufacturing Market?
In the viral and non-viral vector manufacturing markets, technological evolution is increasingly becoming a key trend. To remain competitive in the market, many reputed companies are focusing on creating technologically superior solutions. For example, Merck KGaA, a science and technology firm based in Germany, launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform in August 2022. It’s one of the pioneering Contract development and manufacturing organizations and technology inventors to provide a comprehensive viral vector manufacturing suite, encompassing AAV, Lentiviral, CDMO, CTO, and process development. This groundbreaking platform assists biopharmaceutical firms in reducing process development costs and time while speeding up the transition to clinical manufacturing.
Who Are The Dominant Players In The Viral And Non-Viral Vector Manufacturing Market Today?
Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
Access The Complete Report Here:
What Regional Factors Are Accelerating Growth In The Viral And Non-Viral Vector Manufacturing Market?
North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=12570&type=smp
Browse Through More Reports Similar to the Global Viral And Non-Viral Vector Manufacturing Market 2025, By The Business Research Company
Viral Vectors And Plasmid Dna Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Vector Control Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/vector-control-global-market-report
Viral Inactivation Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model